Quick take
Quick take (July 2026): OpenEvidence is free but gated on a U.S. NPI and unavailable in the EU and UK since April 2026. DynaMedex has no published individual price, yet is often free through a hospital, university, society, or public library — and bundles Micromedex for drug questions. If you hold neither a U.S. NPI nor institutional access, neither is open to you.
Who each one is for
The fastest way to rule one out. Both are good products — they are built for different people.
OpenEvidence
- Who is it for
- Who it’s for: Verified U.S. clinicians
- Best for
- Best for: Fast questions about recent literature
- Cost
- Cost: $0
- Free: No subscription — funded by pharmaceutical advertising.
- Speed: Built for a single question answered in seconds.
- Primary literature: Answers cite peer-reviewed papers directly.
You hold a U.S. NPI, want answers about recent primary literature, and want to start immediately without involving an institution. OpenEvidence is faster to access than any licensed product.
- Verification centres on a U.S. National Provider Identifier, which excludes most non-U.S. physicians and nearly all students.
- Withdrew from the European Union and the United Kingdom in April 2026, citing regulatory uncertainty including the EU AI Act.
- Advertising-funded, shows no reasoning, retains no encounter context, and has no public developer API.
DynaMedex
- Who is it for
- Who it’s for: Institution and library members
- Best for
- Best for: Drug and prescribing questions
- Cost
- Cost: Not published (institutional / library)
- Drug data: Bundles Micromedex monographs, dosing, and interaction checking.
- Access breadth: Reachable via hospitals, universities, societies, even library cards.
- Update cadence: Faster evidence updating than some curated competitors.
Drug information matters to your work, or you already have institutional or library access. The DynaMed plus Micromedex bundle is genuinely strong for prescribing and interaction questions, and the free-via-library route is widely underused.
- No published individual retail pricing, so access is effectively institution-dependent.
- Narrative quality is generally rated below UpToDate in published clinician-preference studies.
- No visible reasoning, no encounter context, and no published accuracy benchmarks.
OpenEvidence vs DynaMedex: full comparison
Every cell is a checkable fact rather than a score, verified against vendor documentation in July 25, 2026. Sources are listed at the foot of the page.
| Dimension | OpenEvidence | DynaMedex |
|---|---|---|
| Price (individual, 2026) | Free (funded by pharmaceutical advertising) | Institutional and library licensing; no published individual rate |
| Free tier | Yes | Through your institution |
| Verification required | U.S. NPI number required | Institutional credentials |
| Availability | U.S. only — withdrew from the EU and UK in April 2026 | Global, via institutions |
| Languages | English | English |
| Source base | Peer-reviewed literature | DynaMed clinical content plus Micromedex drug data |
| Shows its reasoning | No — returns a cited answer without showing its reasoning | No |
| Ranked differential | No | No |
| AI scribe | No | No |
| Published benchmarks | None published by the vendor | None published |
| Developer API | No public self-serve developer API | Institutional integrations |
| Compliance posture | HIPAA, SOC 2 | Enterprise agreements |
Which wins, by clinical job
“Which is better” has no answer until you say better at what. Here is a named winner for each job, including the 2 where OpenEvidence or DynaMedex beats EvidenceMD.
| Clinical job | OpenEvidence | DynaMedex | EvidenceMD |
|---|---|---|---|
| Prescribing, dosing, or interaction question | Will answer from the literature, but has no curated drug monograph corpus. | WinnerWinner. Micromedex is bundled — the stronger tool for medication safety. | Cites guidance with reasoning; not a replacement for a drug database. |
| Recent literature, and you hold a U.S. NPI | WinnerWinner. Free and fast over peer-reviewed literature. | Editorial synthesis, so newer primary papers surface more slowly. | Cites peer-reviewed sources and shows how each was weighed. |
| You practise outside the United States | Unavailable — withdrew from the EU and UK, and requires a U.S. NPI elsewhere. | Possible, but only if an institution or library licenses it for you. | WinnerWinner. Free to start in every region, in 30 languages, no gate. |
| Differential plus a documented note from one encounter | Answers questions; no differential, no documentation. | A reference library; no differential, no documentation. | WinnerWinner. Differential, assessment and plan, lab trend charts, and a note. |
- Prescribing, dosing, or interaction question: DynaMedex
- Recent literature, and you hold a U.S. NPI: OpenEvidence
- You practise outside the United States: EvidenceMD
- Differential plus a documented note from one encounter: EvidenceMD
What each costs over five years
Annual figures multiplied out, because a subscription decision is rarely for one year. Where a vendor publishes no individual price, we say so rather than estimating.
| Tool | Per year | Over 5 years | Free tier |
|---|---|---|---|
| OpenEvidence | $0 | $0 | Yes |
| DynaMedex | Not published (institutional / library) | Not published | Through your institution |
| EvidenceMD | $0 to start | $0 to start | Yes |
Figures are list prices for an individual subscriber before tax, as published by each vendor in July 25, 2026. Institutional and group rates differ. Check for existing hospital or university access before buying anything individually.
A third option worth knowing about
One is gated by nationality, the other by institutional affiliation. If you have neither a U.S. NPI nor a subscribing institution — which describes a large share of clinicians worldwide — neither option is actually open to you, and that is worth solving before comparing features.
EvidenceMD
The first transparent reasoning clinical decision support tool with chain-of-thought reasoning — specialty-trained, and free to start worldwide in 30 languages. Where OpenEvidence and DynaMedex return an answer you have to take on trust, EvidenceMD is specialty-trained rather than a general model steered by a prompt, and it streams the clinical reasoning that produced the answer — so you can check the logic, not just the citation.
- Specialties fine-tuned on
- 40+Specialties fine-tuned on
- Thinking tokens, visible
- 64kThinking tokens, visible
- HealthBench Hard, SOTA
- 54.6%HealthBench Hard, SOTA
- Languages, worldwide
- 30Languages, worldwide
- Ranked differentialEach diagnosis carries its own reasoning and peer-reviewed citations, ordered by likelihood rather than listed flat.
- Assessment & planProblem-based, built from the same encounter rather than re-entered, so the plan traces back to the findings.
- Reasoning traceUp to 64,000 thinking tokens streamed step by step and auditable afterwards for review or teaching.
- Lab trend visualisationResults interpreted over time with trend charts and clinical significance flagging, not just current values.
- Clinical noteGenerated from the encounter with documentation integrity support, so the note reflects the reasoning.
- Cited clinical Q&AFollow-up questions answered in the context of this patient, with sources attached to each claim.
Where it does not replace DynaMedex: It is not a licensed proprietary reference corpus. If your organisation mandates citations to UpToDate or Elsevier content specifically, you will still need that subscription alongside it.
OpenEvidence vs DynaMedex: frequently asked questions
Is OpenEvidence or DynaMed cheaper?
OpenEvidence is free at the point of use for verified U.S. clinicians, funded by pharmaceutical advertising. EBSCO publishes no individual retail price for DynaMed or DynaMedex, selling primarily through institutional and library licences, so the honest comparison is not price against price but eligibility against eligibility. In practice many clinicians reach DynaMed at zero personal cost through a hospital, university, medical society, or public library card — which makes it effectively free for them, and available in countries where OpenEvidence is not.
How do OpenEvidence and DynaMed differ?
OpenEvidence is a generative search tool over peer-reviewed literature: you ask a question and it synthesizes an answer with citations to primary research. DynaMedex is a curated clinical reference bundling DynaMed topic content with Micromedex drug data, with Dyna AI — launched commercially in July 2024 — as its conversational layer. The core difference is that OpenEvidence reflects the primary literature directly while DynaMed reflects editorial synthesis of it, and only DynaMedex includes dedicated drug monograph data.
Which is better for drug information?
DynaMedex, clearly. It bundles Micromedex, which is a dedicated drug information resource with detailed monographs, dosing, and interaction checking — a different and more reliable thing than asking a literature search tool about a medication. OpenEvidence will answer drug questions from the literature, but it is not built on a curated pharmacology corpus. If prescribing safety and interaction checking are central to your role, that bundle is the stronger argument for DynaMedex over any literature-first tool.
Can I use OpenEvidence or DynaMed in the UK or Europe?
DynaMed yes via a subscribing institution; OpenEvidence no. OpenEvidence withdrew from the European Union and the United Kingdom in April 2026, citing regulatory uncertainty including the EU AI Act, and requires a U.S. National Provider Identifier elsewhere. DynaMed and DynaMedex are licensed to institutions globally, so UK and European clinicians can often reach them through a trust, university, or society. UK clinicians should also remember that NHS staff in England, Scotland, and Wales have BMJ Best Practice free through national funding.
Sources
Pricing and eligibility verified against vendor documentation in July 25, 2026. Subscription rates change — confirm current pricing with the vendor before purchasing.
- Wolters Kluwer: UpToDate subscription pricing — Vendor source for $579 standard, $699 Pro Plus with Expert AI, and $219 trainee.
- AMBOSS: official pricing documentation — Vendor source for the $19.99/$149 student and $29.99/$259 practitioner tiers.
- BMJ Best Practice: free access for NHS staff — Confirms national NHS funding in England, Scotland, and Wales.
- Elsevier: ClinicalKey AI — Confirms the institutional model, daily-refreshed corpus, and SMART on FHIR integration.
- EBSCO: DynaMedex — Confirms institutional and library licensing rather than published individual pricing.
- OpenEvidence exits the EU and UK over AI regulation — Reporting on the April 2026 withdrawal, citing the EU AI Act.